The laboratory approach to the diagnosis of autoimmune diseases: is it time to change?
Array technology and proteomics are about to launch the era of multiplexed analysis, which allows simultaneous detection of numerous autoantibody specificities and the possibility of defining broad autoantibody profiles. This will probably improve disease staging, risk stratification, prognosis and treatment. However, although these technologies are very promising, they are still in their infancy, and therefore need to undergo strict analytical and clinical validation processes. The latter should involve clinicians and pathologists in prospective, multicentric studies conducted on large numbers of patients to define the specific significance of the various autoantibody profiles. Establishing common standards for the publication and sharing of microarray-generated data will be important for this purpose. Only when these studies have been completed will these new technologies find a place in clinical laboratories. Although we are entering a decade which will probably see a radical change in the diagnostic approach to autoimmune diseases, we do not yet have sufficient knowledge to apply proteomic technologies on a large scale. For the time being, therefore, it is advisable to continue using well-established approaches and diagnostic algorithms such as those reported in the international guidelines, which have been prepared in accordance with the principles of appropriateness and evidence-based medicine.
Villalta
Danilo
D
Immunologia Clinica e Virologia, Azienda Ospedaliera S. Maria degli Angeli, via Montereale 24, 33170 Pordenone, Italy. danilo.villalta@aopn.fvg.it
Tozzoli
Renato
R
Tonutti
Elio
E
Bizzaro
Nicola
N
D001323:Autoantibodies / Q000097:blood* / Q000276:immunology; D001327:Autoimmune Diseases / Q000175:diagnosis* / Q000276:immunology; D005189:False Positive Reactions; D006801:Humans; D017410:Practice Guidelines as Topic; D040081:Protein Array Analysis / Q000379:methods / Q000592:standards; D040901:Proteomics / Q000379:methods / Q000592:standards; D012680:Sensitivity and Specificity
D001323:Autoantibodies